We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App





Johnson & Johnson Partners with Vibalogics on Development of Lead COVID-19 Vaccine Candidate

By HospiMedica International staff writers
Posted on 20 May 2020
Print article
Image: Johnson & Johnson Partners with Vibalogics on Development of Lead COVID-19 Vaccine Candidate (Photo courtesy of Johnson & Johnson)
Image: Johnson & Johnson Partners with Vibalogics on Development of Lead COVID-19 Vaccine Candidate (Photo courtesy of Johnson & Johnson)
Vibalogics GmbH (Cuxhaven, Germany) will manufacture additional clinical trial material for the lead COVID-19 vaccine candidate currently in development by Johnson & Johnson’s (New Brunswick, NJ, USA) Janssen Pharmaceutical Companies (Beerse, Belgium).

Vibalogics, a global contract development and manufacturing organization that specializes in the production of virotherapy products, is contracted to manufacture multiple batches, which will result in many thousands of doses of an investigational COVID-19 vaccine candidate. Vibalogics will carry out the production at its GMP-accredited facility in Germany where it has recently invested in new equipment to handle larger clinical batches, including a new filling line capable of filling and labeling more than 30,000 vials per batch. Vibalogics is also set to establish a commercial facility in North America for oncolytic viruses, viral vectors for gene therapy approaches and viral vector vaccines in the near future.

“This has been a tremendous challenge for everyone at Vibalogics, but one which the entire team has embraced as an opportunity to use our experience and expertise in the global fight against COVID-19,” said Stefan Beyer, managing director and CEO of Vibalogics. “The business has reacted quickly and efficiently to accommodate this request. With the devotion of our team, and understanding from our customers, we have successfully managed to fulfill this new requirement alongside all of our existing business commitments.”

“This is a fantastic opportunity for the business and our employees to strengthen our position as a global leader in virotherapy manufacturing whilst also providing a key service to our valued customer in its mission to combat the SARS-CoV-2 virus,” added Beyer. “This endeavor is testament to our long-standing and productive partnership with this company, who have shown great trust in our flexible approach, expertise and ability to deliver on time.”

Related Links:
Johnson & Johnson
Janssen Pharmaceutical Companies
Vibalogics GmbH



Print article

Channels

Business

view channel
Image: The Stat EMS Basic blood testing system (Photo courtesy of Nova Biomedical)

Nova's Stat EMS Basic Blood Testing System Launched in CE Mark Countries

Nova Biomedical (Waltham, MA, USA) has launched the Stat EMS Basic blood testing system for ambulance and emergency care in CE mark countries. Stat EMS Basic measures fingerstick capillary lactate, glucose,... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.